Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GAT@F is a cascade catalytic nanoenzyme hydrogel complex developed by researchers at The First Affiliated Hospital of University of South China for the treatment of diabetic wounds. The acronym GAT@F represents its primary active components: **G**lucose oxidase (GOx), **A**u (gold) nanoparticles, and **T**annic acid (TA) integrated with an iron-based framework or nanoparticle carrier (typically **F**e3O4). The therapeutic mechanism involves a cascade reaction where GOx consumes local glucose to produce hydrogen peroxide (H2O2), which is then converted by the Au and Fe nanoenzymes into oxygen (O2) to alleviate wound hypoxia and reactive oxygen species (ROS) to provide antibacterial effects. Tannic acid contributes additional antioxidant, anti-inflammatory, and antibacterial properties. This multi-functional approach aims to regulate the diabetic wound microenvironment, reduce oxidative stress, and promote tissue regeneration in chronic ulcers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on GAT@F.